Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck

Basit Öğe Kaydı
dc.contributor.authorGoksu, Sema Sezgin
dc.contributor.authorTatli, Ali Murat
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorAtci, Mustafa
dc.contributor.authorBesen, Ali Ayberk
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorUysal, Mukremin
dc.date.accessioned2024-02-23T13:43:42Z
dc.date.available2024-02-23T13:43:42Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractPurpose In this study, we looked for whether treatment-induced rash predicts treatment efficacy in patients with recurrent/metastatic HNSCC treated with Cetuximab and chemotherapy. Methods Patients who were treated with platinum-based chemotherapy and cetuximab for the first line treatment of recurrent/metastatic HNSCC were recruited. Presence of rash, hypomagnesemia, hypopotassemia, anemia, neutropenia, thrombocytopenia during treatment and treatment response, date of progression, date of last visit and death were recorded. Results A total of 138 patients' data were available for analysis. Any grade of rash was detected in 57 (44.5%) of the patients. The incidence of rash was significantly higher in patients with objective response than in patients with disease progression (%56.8 vs %14.3, p < 0.001). Progression free survival was 7.06 months (4.98-9.15) in patients treated with cetuximab and chemotherapy as first line treatment. In the multivariate analysis; rash was significantly correlated with longer PFS (HR 2.136; 95% CI 1.067-4.278; p = 0.032). Progression free survival was 9.65 months in patients who experienced rash, and 6.02 months in patients without rash, (p = 0.019, log-rank test). Overall survival was 11.24 months (9.65-12.82). In multivariate analysis, the survival of patients with rash was significantly longer than patients without rash (HR 1.954; 95% CI 1.162-3.285; p = 0.012). Overall survival was 15.08 months in patients who experienced rash, and 8.61 months in patients without rash (p = 0.05, log-rank test). Conclusion Cetuximab-induced rash is associated with better ORR and longer PFS and OS in patients with recurrent/metastatic HNSCC treated with Cetuximab and platinum-based chemotherapy.en_US
dc.identifier.doi10.1007/s00280-021-04328-9
dc.identifier.endpage812en_US
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue5en_US
dc.identifier.pmid34312705en_US
dc.identifier.scopus2-s2.0-85111338342en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage805en_US
dc.identifier.urihttps://doi.org/10.1007/s00280-021-04328-9
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10878
dc.identifier.volume88en_US
dc.identifier.wosWOS:000679012300004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCancer Chemotherapy And Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCetuximaben_US
dc.subjectRashen_US
dc.subjectHead And Necken_US
dc.titleCetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and necken_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu